Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 400 of 2228 entries
View as:

Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT02242227 Org: User:
Start: 09/30/05 End: - Due: -

Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy

Phase: N/A Priority: Normal
NCT ID: NCT00615290 Org: User:
Start: 06/30/07 End: - Due: -

Relative Bioavailability of Tipranavir (TPV)/Ritonavir (RTV) at Steady State Administered as Oral Solutions vs. Capsules in the Fed and Fasted State in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02227017 Org: User:
Start: 02/28/06 End: - Due: -

Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01306162 Org: User:
Start: 02/28/11 End: - Due: -

Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02182349 Org: User:
Start: 06/30/09 End: - Due: -

Iota-Carrageenan Nasal Spray in Common Cold

Phase: N/A Priority: Normal
NCT ID: NCT01944631 Org: User:
Start: 09/30/13 End: 03/31/14 Due: 03/31/15

Assessment of Electrophysiological Effects of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects.

Phase: N/A Priority: Normal
NCT ID: NCT02170987 Org: User:
Start: 03/31/06 End: - Due: -

Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration

Phase: N/A Priority: Normal
NCT ID: NCT01392560 Org: User:
Start: 06/30/11 End: 08/31/12 Due: 08/31/13

An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

Phase: N/A Priority: Normal
NCT ID: NCT05239039 Org: User:
Start: 03/15/22 End: 07/17/23 Due: 07/17/24

A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the Blood

Phase: N/A Priority: Normal
NCT ID: NCT05613777 Org: User:
Start: 11/24/22 End: 10/04/23 Due: 10/04/24

Investigation of the Metabolism and Pharmacokinetics of [14C]BI 1744 CL and [14C]BI 1744 CL Administered as an Oral Solution in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02172157 Org: User:
Start: 02/29/08 End: - Due: -

An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms

Phase: N/A Priority: Normal
NCT ID: NCT01726270 Org: User:
Start: 11/30/12 End: 03/31/13 Due: 03/31/14

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Phase: N/A Priority: Normal
NCT ID: NCT02589626 Org: User:
Start: 10/29/15 End: 06/02/17 Due: 06/02/18

Real-life-persistence to Antifibrotic Treatments

Phase: N/A Priority: Normal
NCT ID: NCT06485635 Org: User:
Start: 10/16/24 End: 06/27/25 Due: 06/27/26

Telmisartan 80mg Non-responder Trial

Phase: N/A Priority: Normal
NCT ID: NCT01222520 Org: User:
Start: 10/31/10 End: - Due: -

Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01167881 Org: User:
Start: 08/31/10 End: 08/31/15 Due: 08/31/16

Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings

Phase: N/A Priority: Normal
NCT ID: NCT02440854 Org: User:
Start: 02/16/16 End: 02/17/21 Due: 02/17/22

Patients With Geographic Atrophy and Their Patient Journey in the United States (US)

Phase: N/A Priority: Normal
NCT ID: NCT05891275 Org: User:
Start: 05/31/23 End: 12/01/23 Due: 12/01/24

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Phase: N/A Priority: Normal
NCT ID: NCT02164864 Org: User:
Start: 07/22/14 End: 06/05/17 Due: 06/05/18

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Phase: N/A Priority: Normal
NCT ID: NCT00736099 Org: User:
Start: 08/31/08 End: - Due: -

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Phase: N/A Priority: Normal
NCT ID: NCT06624670 Org: User:
Start: 02/04/25 End: 10/05/27 Due: 10/05/28

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Phase: N/A Priority: Normal
NCT ID: NCT00243087 Org: User:
Start: 07/31/05 End: - Due: -

Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT01773174 Org: User:
Start: 01/31/13 End: 12/31/15 Due: 12/31/16

Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types

Phase: N/A Priority: Normal
NCT ID: NCT01317420 Org: User:
Start: 04/30/11 End: 02/29/16 Due: 02/28/17

A Study in Healthy Japanese Men to Test How Different Doses of BI 690517 Are Taken Up in the Body and How Well They Are Tolerated

Phase: N/A Priority: Normal
NCT ID: NCT03608072 Org: User:
Start: 08/06/18 End: 01/31/19 Due: 01/31/20